Bal Pharma Limited has informed the Exchange that Board of Directors at its meeting held on May 27, 2026, recommended Final Dividend of Rs. 1.20 per equity share i.e 12%
BALPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Bal Pharma Limited reported FY2026 standalone revenue of Rs 31,080 lakhs, up 2.7% from Rs 30,250 lakhs in FY2025. However, standalone net profit fell to Rs 675 lakhs from Rs 780 lakhs — a decline of about 13.5% year-on-year. Consolidated net profit similarly dropped to Rs 632 lakhs from Rs 724 lakhs. The Board recommended a final dividend of Rs 1.20 per share (12% on Rs 10 face value), subject to shareholder approval. Other decisions include appointment of new internal and cost auditors, grant of 5 lakh stock options to employees, and a preferential issue of 10 lakh warrants to promoters. Statutory auditors issued an unmodified (clean) opinion on both standalone and consolidated results.
Revenue growth is marginal at ~3%, while PAT declined significantly — a red flag for cost efficiency. The clean audit opinion and dividend signal management confidence, but the profit decline and inventory buildup warrant close monitoring. The promoter warrant issuance will dilute equity if converted.